BioNTech SE (BNTX) Change in Receivables (2020 - 2025)
BioNTech SE (BNTX) posted Change in Receivables of $94.3 million for Q4 2025, down 90.85% sequentially from $1.0 billion in Q3 2025, and up 110.03% YoY from $44.9 million in Q4 2024.
BioNTech SE (BNTX) Change in Receivables (2020 - 2025) Analysis & Trends
BioNTech SE has reported Change in Receivables for 6 years, with the latest figure at $94.3 million in Q4 2025.
- Quarterly Change in Receivables rose 110.03% year-over-year to $94.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $775.0 million (down 82.07% YoY) and the FY2025 annual result came in at $1.2 billion, up 195.53% from the prior year.
- Change in Receivables slipped to $94.3 million in Q4 2025 per BNTX's latest filing, from $1.0 billion in the prior quarter.
- Over five years, Change in Receivables peaked at $5.1 billion in Q3 2022 and troughed at -$11.9 billion in Q3 2021.
- A 5-year average of -$278.1 million and a median of $342.2 million in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2021 and 2023: Change in Receivables plunged 851445957.2% in 2021, then soared 774.52% in 2023.
- Over 5 years, Change in Receivables stood at -$2.0 billion in 2021, then soared by 66.32% to -$659.9 million in 2022, then jumped by 774.52% to $4.5 billion in 2023, then sank by 121.12% to -$940.3 million in 2024, then soared by 110.03% to $94.3 million in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered $94.3 million, $1.0 billion, and $590.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 94.29 Mn |
| Dec 31, 2025 | 94.29 Mn |
| Sep 30, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 590.20 Mn |
| Jun 30, 2025 | 590.20 Mn |
| Dec 31, 2024 | -940.26 Mn |
| Dec 31, 2024 | -940.26 Mn |
| Sep 30, 2024 | -911.74 Mn |
| Sep 30, 2024 | -911.74 Mn |
| Jun 30, 2024 | 1.72 Bn |
| Jun 30, 2024 | 1.72 Bn |
| Dec 31, 2023 | 4.45 Bn |
| Dec 31, 2023 | 4.45 Bn |
| Sep 30, 2023 | 687.12 Mn |
| Sep 30, 2023 | 687.12 Mn |
| Mar 31, 2023 | 959.35 Mn |
| Mar 31, 2023 | 959.35 Mn |
| Dec 31, 2022 | -659.90 Mn |
| Dec 31, 2022 | -659.90 Mn |